The angiotensin II type 2 receptor activates flow-mediated outward remodelling through T cells-dependent interleukin-17 production

Cardiovasc Res. 2016 Oct;112(1):515-25. doi: 10.1093/cvr/cvw172. Epub 2016 Jun 21.

Abstract

Aims: The angiotensin II type 1 receptor (AT1R) through the activation of immune cells plays a key role in arterial inward remodelling and reduced blood flow in cardiovascular disorders. On the other side, flow (shear stress)-mediated outward remodelling (FMR), involved in collateral arteries growth in ischaemic diseases, allows revascularization. We hypothesized that the type 2 receptor (AT2R), described as opposing the effects of AT1R, could be involved in FMR.

Methods and results: We studied FMR using a model of ligation of feed arteries supplying collateral pathways in the mouse mesenteric arterial bed in vivo. Seven days after ligation, diameter increased by 30% in high flow (HF) arteries compared with normal flow vessels. FMR was absent in mice lacking AT2R. At Day 2, T lymphocytes expressing AT2R were present preferentially around HF arteries. FMR did not occur in athymic (nude) mice lacking T cells and in mice treated with anti-CD3ε antibodies. AT2R activation induced interleukin-17 production by memory T cells. Treatment of nude mice or AT2R-deficient mice with interleukin-17 restored diameter enlargement in HF arteries. Interleukin-17 increased NO-dependent relaxation and matrix metalloproteinases activity, both important in FMR. Remodelling of feeding arteries in the skin flap model of ischaemia was also absent in AT2R-deficient mice and in anti-interleukin-17-treated mice. Finally, remodelling, absent in 12-month-old mice, was restored by a treatment with the AT2R non-peptidic agonist C21.

Conclusion: AT2R-dependent interleukin-17 production by T lymphocyte is necessary for collateral artery growth and could represent a new therapeutic target in ischaemic disorders.

Keywords: Angiotensin II type 2 receptor; Blood flow; Collateral artery growth; Interleukin-17.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Animals
  • Arterial Pressure
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism*
  • Collateral Circulation
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Genotype
  • Interleukin-17 / metabolism*
  • Ischemia / genetics
  • Ischemia / immunology
  • Ischemia / metabolism*
  • Ischemia / physiopathology
  • Ligation
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Mechanotransduction, Cellular* / drug effects
  • Mesenteric Arteries / drug effects
  • Mesenteric Arteries / immunology
  • Mesenteric Arteries / metabolism*
  • Mesenteric Arteries / surgery
  • Mesentery / blood supply*
  • Mice
  • Mice, Knockout
  • Mice, Nude
  • Phenotype
  • RAW 264.7 Cells
  • Receptor, Angiotensin, Type 2 / agonists
  • Receptor, Angiotensin, Type 2 / deficiency
  • Receptor, Angiotensin, Type 2 / genetics
  • Receptor, Angiotensin, Type 2 / metabolism*
  • Regional Blood Flow
  • Skin / blood supply*
  • Splanchnic Circulation* / drug effects
  • Stress, Mechanical
  • Time Factors
  • Vascular Remodeling*
  • Vascular Resistance
  • Vasodilation

Substances

  • Interleukin-17
  • Receptor, Angiotensin, Type 2